MRK - Merck & Co., Inc.

Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) pathway, for the treatment of diabetic macular edema (DME). Results were presented today at the.

Oct 10, 2026 02:10 PM • businesswire.com

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk commands a premium on exceptional profitability and GLP-1 dominance.

Oct 10, 2026 08:13 AM • fool.com

Breakfast News: The Quarter in Charts

The market made a modest gain - but most stocks got left behind.

Oct 10, 2026 03:30 AM • fool.com

This Stock Is Up More than 560% This Year, but It Could Drop by 38%, According to Wall Street

Have Moderna's shares risen too much, too fast?

Oct 09, 2026 12:00 PM • fool.com

Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies

Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the biggest gain of the group. Novavax (NASDAQ:NVAX) shares recently changed hands at $12.77, up 16%.

Oct 09, 2026 09:59 AM • 247wallst.com

Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks

Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVie, Merck, and Pfizer, but higher targets do not mean equal conviction.

Oct 09, 2026 04:00 AM • 247wallst.com

Merck & Co., Inc. $MRK Stake Raised by GAMMA Investing LLC

GAMMA Investing LLC lifted its stake in Merck and Co., Inc. (NYSE: MRK) by 5.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 100,519 shares of the company's stock after purchasing an additional 5,527 shares during the

Oct 09, 2026 02:22 AM • defenseworld.net

Apella Capital LLC Increases Stake in Merck & Co., Inc. $MRK

Apella Capital LLC grew its position in shares of Merck and Co., Inc. (NYSE: MRK) by 16.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 43,902 shares of the company's stock after acquiring an additional 6,239 shares

Oct 09, 2026 01:46 AM • defenseworld.net

Farther Finance Advisors LLC Acquires 11,956 Shares of Merck & Co., Inc. $MRK

Farther Finance Advisors LLC boosted its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 9.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 132,641 shares of the company's stock after buying an additional 11,956 shares during the quarter. Farther

Oct 09, 2026 01:12 AM • defenseworld.net

HALO Wins Court Order Blocking Merck's Keytruda SC in Europe

Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.

Oct 08, 2026 09:51 AM • zacks.com

INVA vs. MRK: Which Stock Is the Better Value Option?

Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Innoviva (INVA) or Merck (MRK). But which of these two stocks is more attractive to value investors?

Oct 08, 2026 08:40 AM • zacks.com

HP, Merck, and Seagate Just Paid Their Shareholders. Here's What Landed in Their Accounts.

On October 7, three companies with nothing in common sent cash to their shareholders, but the differences in what each paid, how fast each raised it, and what the stock price does to the math tell three very different income

Oct 08, 2026 04:20 AM • 247wallst.com

3 Stocks That Have More Than Doubled the S&P 500’s Return This Year

Three stocks left the S&P 500's 2025 return in the dust, but gains that large raise one uncomfortable question: is the opportunity already gone, or does one of them still have a real runway ahead?

Oct 08, 2026 03:30 AM • 247wallst.com

Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure

Tempus Inc. (NASDAQ:TEM) on Wednesday expanded its multi-year collaboration for intismeran autogene (V940/mRNA-4157) individualized neoantigen therapy (INT) combined with Keytruda (pembrolizumab) for completely resected stage IIB-IV melanoma and other cancer types.

Oct 07, 2026 09:44 AM • benzinga.com

Merck's Keytruda Is Dealt a Legal Setback. It's Good News for This Biotech Stock.

A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European markets.

Oct 07, 2026 08:20 AM • barrons.com

Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know

Merck (MRK) reached $141.94 at the closing of the latest trading day, reflecting a +1.72% change compared to its last close.

Oct 06, 2026 02:51 PM • zacks.com

Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity?

Merck's 7% dip may offer a buying opportunity as Keytruda drives growth and new products and pipeline assets strengthen its post-2028 outlook.

Oct 06, 2026 08:36 AM • zacks.com

Merck & Co., Inc. $MRK Stock Position Decreased by Park National Corp OH

Park National Corp OH trimmed its stake in Merck and Co., Inc. (NYSE: MRK) by 6.1% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 120,805 shares of the company's stock after selling 7,788 shares during the quarter. Park National Corp OH's

Oct 05, 2026 11:13 AM • defenseworld.net

Merck & Co., Inc. $MRK Shares Sold by Ferguson Wellman Capital Management Inc.

Ferguson Wellman Capital Management Inc. lessened its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 1.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 369,628 shares of the company's stock after selling 7,016 shares

Oct 05, 2026 10:24 AM • defenseworld.net

Rockland Trust Co. Lowers Stake in Merck & Co., Inc. $MRK

Rockland Trust Co. lowered its position in Merck and Co., Inc. (NYSE: MRK) by 6.5% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 458,433 shares of the company's stock after selling 31,616 shares during the quarter. Merck and Co., Inc. comprises 2.5%

Oct 05, 2026 10:24 AM • defenseworld.net

Merck (MRK) PT Raised to $145 at Cantor Fitzgerald - Outstanding ESMO Expected

$145.00 (was $142.79)

Carter Gould · Cantor Fitzgerald

Oct 08, 2026 07:16 AM • StreetInsider

Merck price target raised to $180 from $155 at Scotiabank

$180.00 (was $147.15)

Scotiabank

Sep 29, 2026 10:04 AM • TheFly

Merck (MRK) PT Raised to $137 at Berenberg

$137.00 (was $144.71)

Luisa Hector · Berenberg Bank

Sep 11, 2026 02:44 AM • StreetInsider

Merck price target raised to $172 from $150 at HSBC

$172.00 (was $147.60)

HSBC

Sep 10, 2026 06:24 AM • TheFly

Merck price target raised to $161 from $127 at Leerink

$161.00 (was $148.49)

Leerink Partners

Sep 09, 2026 06:09 AM • TheFly

Merck (MRK) PT Raised to $170 at Guggenheim

$170.00 (was $150.34)

Vamil Divan · Guggenheim

Sep 08, 2026 07:16 AM • StreetInsider

Merck price target raised to $170 from $150 at Wells Fargo

$170.00 (was $152.34)

Wells Fargo

Sep 04, 2026 06:37 AM • TheFly

Merck price target raised to $170 from $145 at Argus

$170.00 (was $153.61)

Jasper Hellweg · Argus Research

Aug 25, 2026 08:07 AM • TheFly

Merck price target raised to $180 from $155 at Wolfe Research

$180.00 (was $150.69)

Alexandria Hammond · Wolfe Research

Aug 25, 2026 05:52 AM • TheFly

Merck price target raised to $160 from $140 at Goldman Sachs

$160.00 (was $149.25)

Goldman Sachs

Aug 21, 2026 06:25 AM • TheFly

Merck price target raised to $170 from $142 at BMO Capital

$170.00 (was $149.65)

BMO Capital

Aug 20, 2026 08:47 AM • TheFly

Merck price target raised to $175 from $145 at UBS

$175.00 (was $152.22)

UBS

Aug 20, 2026 06:44 AM • TheFly

Merck downgraded to Sector Perform from Outperform at RBC Capital

$150.00 (was $152.22)

RBC Capital

Aug 20, 2026 05:04 AM • TheFly

UBS Downgrades Merck (MRK) to Neutral

$150.00 (was $152.22)

Matthew Weston · UBS

Aug 20, 2026 02:49 AM • StreetInsider

Merck upgraded to Overweight from Equal Weight at Morgan Stanley

$179.00 (was $152.22)

Morgan Stanley

Aug 19, 2026 04:28 PM • TheFly

Daiwa upgrades Merck to Outperform on pipeline success

$143.00 (was $130.45)

Daiwa

Aug 12, 2026 05:51 AM • TheFly

Merck (MRK) PT Raised to $145 at Argus

$145.00 (was $130.90)

Jasper Hellweg · Argus Research

Aug 11, 2026 07:12 AM • StreetInsider

Merck price target raised to $116 from $113 at Morgan Stanley

$116.00 (was $130.40)

Terence Flynn · Morgan Stanley

Aug 05, 2026 08:40 AM • TheFly

Merck price target raised to $146 from $145 at Guggenheim

$146.00 (was $128.04)

Vamil Divan · Guggenheim

Aug 05, 2026 07:21 AM • TheFly

Merck price target raised to $150 from $140 at Barclays

$150.00 (was $131.84)

Emily Field · Barclays

Jul 29, 2026 05:07 AM • TheFly